Drugs

Article	Citations
Prevention and Treatment of Monkeypox	313
BNT162b2 mRNA COVID-19 Vaccine: First Approval	224
Pharmaco-Immunomodulatory Therapy in COVID-19	191
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	174
Inclisiran: First Approval	170
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	167
Lumasiran: First Approval	167
Remdesivir: First Approval	166
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	164
Nirmatrelvir Plus Ritonavir: First Approval	156
Casimersen: First Approval	135
Sacituzumab Govitecan: First Approval	134
Pemigatinib: First Approval	127
Aducanumab: First Approval	114
Viltolarsen: First Approval	114
Sotorasib: First Approval	112
Risdiplam: First Approval	99
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	92
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma	92
Acute Pancreatitis: Diagnosis and Treatment	92
Setmelanotide: First Approval	91
TRPV1-Targeted Drugs in Development for Human Pain Conditions	91
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	90
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	88
Selpercatinib: First Approval	86

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	85
Bulevirtide: First Approval	84
Belantamab Mafodotin: First Approval	83
Remimazolam: First Approval	83
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?	83
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	80
Pharmacokinetics and Pharmacodynamics of Posaconazole	79
Orelabrutinib: First Approval	79
Inhaled Liposomal Antimicrobial Delivery in Lung Infections	73
Ozanimod: First Approval	72
Nivolumab Plus Relatlimab: First Approval	72
New and Emerging Systemic Treatments for Atopic Dermatitis	72
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer	71
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review	69
REGN-EB3: First Approval	68
Tirabrutinib: First Approval	67
Selumetinib: First Approval	67
Fabry Disease: The Current Treatment Landscape	66
Lonafarnib: First Approval	66
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials	66
Amivantamab: First Approval	65
Pralsetinib: First Approval	63
Capmatinib: First Approval	62
Decitabine/Cedazuridine: First Approval	62
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety	61
Belzutifan: First Approval	60
Inebilizumab: First Approval	60
Savolitinib: First Approval	60
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	58
Bempedoic Acid: First Approval	57
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	56
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	56
Remimazolam: A Review in Procedural Sedation	56
Deucravacitinib: First Approval	55
Faricimab: First Approval	54
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review	54
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma	53
Molnupiravir: First Approval	52
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	51
Casirivimab/Imdevimab: First Approval	51
Tepotinib: First Approval	51
Targeting AMPK by Statins: A Potential Therapeutic Approach	50
Tisotumab Vedotin: First Approval	50
Tucatinib: First Approval	49
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	49
Disitamab Vedotin: First Approval	48
Dostarlimab: First Approval	48
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma	48
Abrocitinib: First Approval	47
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation	47

Efgartigimod: First Approval	46
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	46
Loncastuximab Tesirine: First Approval	46
Current Status of Clinical Trials on Tau Immunotherapies	46
Filgotinib: First Approval	45
Lurbinectedin: First Approval	45
Management of Thrombotic Complications in COVID-19: An Update	45
Contezolid: First Approval	45
Vutrisiran: First Approval	44
Ripretinib: First Approval	44
Trilaciclib: First Approval	44
Telitacicept: First Approval	44
The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19	44
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer	44
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	44
Umbralisib: First Approval	43
Odevixibat: First Approval	43
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	43
Daprodustat: First Approval	42
Pegcetacoplan: First Approval	42
Cabotegravir Plus Rilpivirine: First Approval	42
Infigratinib: First Approval	42
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	42
Tirzepatide: First Approval	41
Naxitamab: First Approval	41
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review	41
Isatuximab: First Approval	40
Envafolimab: First Approval	40
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	40
Therapeutic Options in Hereditary Optic Neuropathies	40
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs	39
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma	39
Lecanemab: First Approval	39
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder	39
Anifrolumab: First Approval	38
Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon	38
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics	38
Rimegepant: First Approval	38
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals	37
Satralizumab: First Approval	37
Cadonilimab: First Approval	37
Regdanvimab: First Approval	37
Givosiran: A Review in Acute Hepatic Porphyria	37
Voclosporin: First Approval	36
Tebentafusp: First Approval	36
Lazertinib: First Approval	36
Tezepelumab: First Approval	36
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents	36
Ocrelizumab: A Review in Multiple Sclerosis	36
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists	35
Functional Dyspepsia: Diagnostic and Therapeutic Approaches	35
Eptinezumab: First Approval	35
Evinacumab: First Approval	35
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review	35
Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates	35
Melphalan Flufenamide (Melflufen): First Approval	34
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?	34
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy	34
Mavacamten: First Approval	33
Tremelimumab: First Approval	33
Vadadustat: First Approval	33
Sotrovimab: First Approval	33
Fuzuloparib: First Approval	33
Daridorexant: First Approval	33
Asciminib: First Approval	32
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?	32
Spesolimab: First Approval	32
Mosunetuzumab: First Approval	32
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps	31
Finerenone: First Approval	31
Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza	31
Teclistamab: First Approval	31
Avacopan: First Approval	31
Pamiparib: First Approval	31
Tixagevimab + Cilgavimab: First Approval	30
Nirsevimab: First Approval	30
Oliceridine: First Approval	30
Mobocertinib: First Approval	30
Vericiguat: First Approval	30
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease	29

Olverembatinib: First Approval	29
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	29
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	29
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes	29
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents	29
Mirvetuximab Soravtansine: First Approval	29
Belumosudil: First Approval	28
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry	28
Ansuvimab: First Approval	28
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics	28
Difelikefalin: First Approval	28
Maralixibat: First Approval	28
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections	28
Uveitis Therapy: The Corticosteroid Options	27
Novel Approaches Towards a Functional Cure of HIV/AIDS	27
Tapinarof Cream 1%: First Approval	27
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)	27
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	27
Atogepant: First Approval	27
Donafenib: First Approval	26
Ozoralizumab: First Approval	26
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa	26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	26
Margetuximab: First Approval	25
Ibrexafungerp: First Approval	25
Adagrasib: First Approval	25
Hetrombopag: First Approval	25
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	24
Fostemsavir: First Approval	24
Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials	24
Maribavir: First Approval	24
Post-Thoracotomy Pain: Current Strategies for Prevention and Treatment	24
New and Emerging Therapies for Alopecia Areata	24
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?	23
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars	23
Secukinumab: A Review in Psoriatic Arthritis	23
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC	23
Tralokinumab: First Approval	23
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies	23
Etranacogene Dezaparvovec: First Approval	23
Lenacapavir: First Approval	23
Valoctocogene Roxaparvovec: First Approval	23
New Agents in Development for Sepsis: Any Reason for Hope?	23
Oteseconazole: First Approval	23
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease	23
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update	23
The Expanding Role of the COX Inhibitor/Opioid Receptor Agonist Combination in the Management of Pain	22
Futibatinib: First Approval	22
Enarodustat: First Approval	22
Nemolizumab: First Approval	22
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review	22
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	22
Furmonertinib: First Approval	22
Triheptanoin: First Approval	22
Ocular Toxicity of Targeted Anticancer Agents	21
Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent	21
Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists	21
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity	21
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice	21
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease	21
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives	21
Ponesimod: First Approval	20
Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach	20
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review	20
Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation	20
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia	20
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis	20
Ganaxolone: First Approval	20
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	20
New Topical Therapies in Development for Atopic Dermatitis	20
Pacritinib: First Approval	19
A New Paradigm for Achieving a Rapid Antidepressant Response	19
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	19
Tofersen: First Approval	19
Strategies for the Prevention and Treatment of Iatrogenic Withdrawal from Opioids and Benzodiazepines in Critically Ill Neonates, Children and Adults: A Systematic Review of Clinical Studies	19
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?	19
Potential for Harm Associated with Discharge Opioids After Hospital Stay: A Systematic Review	19
Avatrombopag: A Review in Thrombocytopenia	18
Olanzapine/Samidorphan: First Approval	18
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density	18
Pathophysiology and Management of Variceal Bleeding	18
Olipudase Alfa: First Approval	18
Personalized Multimorbidity Management for Patients with Type 2 Diabetes Using Reinforcement Learning of Electronic Health Records	18
Estetrol/Drospirenone: A Review in Oral Contraception	18
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020	18
Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors	18
Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?	18
The Potential Role of Clinical Metagenomics in Infectious Diseases: Therapeutic Perspectives	18
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis	18
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	18
Omaveloxolone: First Approval	18
Tafasitamab: First Approval	18
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	18
Bimekizumab for the Treatment of Psoriasis	17
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer	17